The differences in immunogenicity of TP53 mutated endometrial-, high-grade serous ovarian- and triple negative breast carcinomas

被引：0
|
作者：
Zeimet, A. G. [1 ]
Leitner, K. [1 ]
Hackl, H. [2 ]
Fiegl, H. [1 ]
Feroz, B. [1 ]
Marth, C. [1 ]
Steger, K. [1 ]
机构：
[1] Med Univ Innsbruck, Gynecol & Obstet, Innsbruck, Austria
[2] Med Univ Innsbruck, Inst Bioinformat, Innsbruck, Austria
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
792P
引用
收藏
页码：S591 / S591
页数：1
相关论文
共 50 条
  • [41] Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models
    Perets, Ruth
    Wyant, Gregory A.
    Muto, Katherine W.
    Bijron, Jonathan G.
    Poole, Barish B.
    Chin, Kenneth T.
    Chen, Jin Yun H.
    Ohman, Anders W.
    Stepule, Corey D.
    Kwak, Soongu
    Karst, Alison M.
    Hirsch, Michelle S.
    Setlur, Sunita R.
    Crum, Christopher P.
    Dinulescu, Daniela M.
    Drapkin, Ronny
    CANCER CELL, 2013, 24 (06) : 751 - 765
  • [42] Studying the effect of germline polymorphisms on somatic hotspot mutations in TP53 for the treatment of high-grade serous ovarian carcinoma.
    de Souza, Cristabelle Madona N.
    Chien, Jeremy
    Madden, Jill
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 103 - 104
  • [43] Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries
    Anglesio, Michael S.
    O'Neill, Ciaran J.
    Senz, Janine
    Gilks, C. Blake
    McCluggage, W. Glenn
    HISTOPATHOLOGY, 2017, 71 (06) : 1014 - 1017
  • [44] Clinical utility of monitoring TP53 mutation (TP53m) circulating tumour DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC)
    Kfoury, M.
    Bonnet, C.
    Delanoy, N.
    Leformal, A.
    Brizais, C.
    Howarth, K.
    Morris, C.
    Pautier, P.
    Colomba-Blameble, E.
    Gouy, S.
    Morice, P.
    Maulard, A.
    Elodie, L.
    Leary, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S632 - S632
  • [45] Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
    Alba Mota
    Juan Carlos Triviño
    Alejandro Rojo-Sebastian
    Ángel Martínez-Ramírez
    Luis Chiva
    Antonio González-Martín
    Juan F. Garcia
    Pablo Garcia-Sanz
    Gema Moreno-Bueno
    BMC Cancer, 15
  • [46] Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
    Mota, Alba
    Carlos Trivino, Juan
    Rojo-Sebastian, Alejandro
    Martinez-Ramirez, Angel
    Chiva, Luis
    Gonzalez-Martin, Antonio
    Garcia, Juan F.
    Garcia-Sanz, Pablo
    Moreno-Bueno, Gema
    BMC CANCER, 2015, 15
  • [47] Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas
    Matsumoto, Nana
    Manrai, Padmini
    Rottmann, Douglas
    Wu, Xinyu
    Assem, Hisham
    Hui, Pei
    Buza, Natalia
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2023, 42 (06) : 567 - 575
  • [48] TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma
    Lawson, Barrett C.
    Yang, Richard K.
    Euscher, Elizabeth D.
    Ramalingam, Preetha
    Malpica, Anais
    HUMAN PATHOLOGY, 2021, 115 : 76 - 83
  • [49] TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer
    Vitale, Silvia R.
    Groenendijk, Floris H.
    van Marion, Ronald
    Beaufort, Corine M.
    Helmijr, Jean C.
    Dubbink, Hendrikus Jan
    Dinjens, Winand N. M.
    Ewing-Graham, Patricia C.
    Smolders, Ramon
    van Doorn, Helena C.
    Boere, Ingrid A.
    Berns, Els M. J. J.
    Helleman, Jozien
    Jansen, Maurice P. H. M.
    BIOMOLECULES, 2020, 10 (03)
  • [50] TP53 alteration in morphologically benign breast tissue in patients with ER/PR negative high grade breast carcinomas: Marker for early detection of high risk patients for high grade carcinomas?
    Wang, Xi
    Stolla, Moritz
    Laughlin, Todd S.
    Rothberg, Paul G.
    Skinner, Kristin
    Hicks, David G.
    CANCER RESEARCH, 2015, 75
12345